DE4031881C2
(de)
*
|
1990-10-08 |
1994-02-24 |
Sanol Arznei Schwarz Gmbh |
Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung
|
AU1537292A
(en)
†
|
1991-04-16 |
1992-11-17 |
Nippon Shinyaku Co. Ltd. |
Method of manufacturing solid dispersion
|
WO1993013758A1
(en)
*
|
1992-01-13 |
1993-07-22 |
Pfizer Inc. |
Preparation of tablets of increased strength
|
JPH0656659A
(ja)
*
|
1992-06-10 |
1994-03-01 |
Natl Sci Council |
直接打錠できる薬学組成物及びその錠剤の製造法
|
EP0665010B1
(en)
*
|
1992-10-16 |
2002-09-11 |
Nippon Shinyaku Company, Limited |
Method of manufacturing wax matrices
|
IL110139A0
(en)
*
|
1993-06-28 |
1994-10-07 |
Howard Foundation |
Pharmaceutically-active antioxidants
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
DE19629753A1
(de)
|
1996-07-23 |
1998-01-29 |
Basf Ag |
Verfahren zur Herstellung von festen Arzneiformen
|
TW474824B
(en)
|
1996-09-13 |
2002-02-01 |
Basf Ag |
The production of solid pharmaceutical forms
|
DE19710213A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Verfahren zur Herstellung von festen Kombinationsarzneiformen
|
DE19753298A1
(de)
|
1997-12-01 |
1999-06-02 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
RS50070B
(sr)
|
1997-12-22 |
2009-01-22 |
Euro-Celtique S.A., |
Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
|
DE19812688A1
(de)
|
1998-03-23 |
1999-09-30 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
DE19840256A1
(de)
|
1998-09-03 |
2000-03-09 |
Basf Ag |
Verfahren zur Herstellung von beschichteten festen Dosierungsformen
|
DE19841244A1
(de)
|
1998-09-09 |
2000-03-16 |
Knoll Ag |
Verfahren und Vorrichtung zum Herstellen von Tabletten
|
DE19843904A1
(de)
|
1998-09-24 |
2000-03-30 |
Basf Ag |
Feste Dosierungsform mit polymerem Bindemittel
|
DE19847618A1
(de)
|
1998-10-15 |
2000-04-20 |
Basf Ag |
Verfahren zur Herstellung von festen Dosierungsformen
|
DE19901383A1
(de)
|
1999-01-15 |
2000-07-20 |
Knoll Ag |
Verfahren zur Herstellung unterschiedlicher fester Dosierungsformen
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
ATE526950T1
(de)
|
1999-10-29 |
2011-10-15 |
Euro Celtique Sa |
Hydrocodon-formulierungen mit gesteuerter freisetzung
|
JP5767429B2
(ja)
*
|
1999-11-12 |
2015-08-19 |
アッヴィ・インコーポレイテッド |
固体分散剤中の結晶化阻害剤
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
DE19960494A1
(de)
*
|
1999-12-15 |
2001-06-21 |
Knoll Ag |
Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
|
EP1255547B1
(en)
|
2000-02-08 |
2008-08-20 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
EP2517710B1
(en)
|
2000-02-08 |
2015-03-25 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
DE10017102A1
(de)
|
2000-04-06 |
2001-10-11 |
Basf Ag |
Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
EP2263658A1
(en)
|
2000-10-30 |
2010-12-22 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
CN1525851A
(zh)
|
2001-05-11 |
2004-09-01 |
������ҩ������˾ |
抗滥用阿片样物质控释剂型
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
DK2425824T5
(en)
|
2002-04-05 |
2018-02-12 |
Mundipharma As |
Pharmaceutical preparation containing oxycodone and naloxone
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
EP2422772A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
DE10247037A1
(de)
*
|
2002-10-09 |
2004-04-22 |
Abbott Gmbh & Co. Kg |
Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers
|
JP4865330B2
(ja)
|
2002-12-13 |
2012-02-01 |
デュレクト コーポレーション |
経口ドラッグデリバリーシステム
|
EP1572190B1
(en)
*
|
2002-12-17 |
2007-04-18 |
Abbott GmbH & Co. KG |
Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
|
US20080051411A1
(en)
*
|
2002-12-17 |
2008-02-28 |
Cink Russell D |
Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
|
JP2006518380A
(ja)
*
|
2003-01-31 |
2006-08-10 |
スミスクライン・ビーチャム・コーポレイション |
固体分散体組成物
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
WO2004093819A2
(en)
|
2003-04-21 |
2004-11-04 |
Euro-Celtique, S.A. |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
US8377952B2
(en)
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
EP1663229B1
(en)
|
2003-09-25 |
2010-04-14 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
BRPI0417348A
(pt)
*
|
2003-12-04 |
2007-03-13 |
Pfizer Prod Inc |
processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
|
US6984403B2
(en)
*
|
2003-12-04 |
2006-01-10 |
Pfizer Inc. |
Azithromycin dosage forms with reduced side effects
|
WO2005053652A1
(en)
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
|
EP1694304A2
(en)
*
|
2003-12-04 |
2006-08-30 |
Pfizer Products Inc. |
Azithromycin multiparticulate dosage forms by liquid-based processes
|
WO2005053639A2
(en)
*
|
2003-12-04 |
2005-06-16 |
Pfizer Products Inc. |
Controlled release multiparticulates formed with dissolution enhancers
|
JP2007513143A
(ja)
*
|
2003-12-04 |
2007-05-24 |
ファイザー・プロダクツ・インク |
押出機を使用して好ましくはポロクサマーおよびグリセリドを含む多粒子アジスロマイシン組成物を製造するための噴霧凝固法
|
SI1691787T1
(sl)
*
|
2003-12-04 |
2008-10-31 |
Pfizer Prod Inc |
Postopek za pripravo farmacevtskih produktov iz več delcev
|
EP1691786A1
(en)
*
|
2003-12-04 |
2006-08-23 |
Pfizer Products Inc. |
Multiparticulate compositions with improved stability
|
ES2281851T3
(es)
*
|
2003-12-09 |
2007-10-01 |
Euro-Celtique S.A. |
Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
EP1691811B1
(en)
|
2003-12-11 |
2014-07-23 |
Sunovion Pharmaceuticals Inc. |
Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
|
TWI483944B
(zh)
|
2004-03-30 |
2015-05-11 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
PT1729730E
(pt)
|
2004-03-30 |
2009-04-06 |
Euro Celtique Sa |
Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso
|
WO2005115343A2
(de)
|
2004-05-28 |
2005-12-08 |
Abbott Gmbh & Co. Kg |
Dosierungsform, erhältlich aus einer ein anorganisches pigment umfassenden pulvermischung
|
EP1604667A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
SI1765292T1
(en)
|
2004-06-12 |
2018-04-30 |
Collegium Pharmaceutical, Inc. |
Formulations of medicines to discourage abuse
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
KR20090029856A
(ko)
*
|
2005-01-28 |
2009-03-23 |
유로-셀띠끄 소시에떼 아노님 |
알코올 저항성 제형
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
ATE476997T1
(de)
*
|
2005-07-05 |
2010-08-15 |
Abbott Gmbh & Co Kg |
Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
|
US20090028938A1
(en)
|
2005-08-08 |
2009-01-29 |
Abbott Gmbh & Co. Kg |
Dosage forms with improved bioavailability
|
EP1912625B1
(en)
|
2005-08-08 |
2016-04-13 |
AbbVie Deutschland GmbH & Co KG |
Itraconazole compositions with improved bioavailability
|
SG169334A1
(en)
*
|
2006-01-21 |
2011-03-30 |
Abbott Gmbh & Co Kg |
Dosage form and method for the delivery of drugs of abuse
|
EP1813276A1
(en)
*
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Tamper resistant dosage forms
|
EP1832281A1
(en)
*
|
2006-03-10 |
2007-09-12 |
Abbott GmbH & Co. KG |
Process for producing a solid dispersion of an active ingredient
|
KR101486228B1
(ko)
|
2006-06-19 |
2015-01-26 |
알파마 파머슈티컬스 엘엘씨 |
약제학적 조성물
|
WO2008067164A2
(en)
*
|
2006-11-15 |
2008-06-05 |
Abbott Laboratories |
Solid pharmaceutical dosage formulations
|
GB0624880D0
(en)
*
|
2006-12-14 |
2007-01-24 |
Johnson Matthey Plc |
Improved method for making analgesics
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
AU2008347158B8
(en)
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
BRPI0906467C1
(pt)
|
2008-01-25 |
2021-05-25 |
Gruenenthal Gmbh |
forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada
|
KR101690094B1
(ko)
|
2008-05-09 |
2016-12-27 |
그뤼넨탈 게엠베하 |
분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
WO2010103039A1
(en)
|
2009-03-10 |
2010-09-16 |
Euro-Celtique S.A. |
Immediate release pharmaceutical compositions comprising oxycodone and naloxone
|
WO2011009604A1
(en)
|
2009-07-22 |
2011-01-27 |
Grünenthal GmbH |
Oxidation-stabilized tamper-resistant dosage form
|
PE20121067A1
(es)
|
2009-07-22 |
2012-09-05 |
Gruenenthal Chemie |
Forma de dosificacion de liberacion controlada extruida por fusion en caliente
|
JP2013505210A
(ja)
*
|
2009-09-18 |
2013-02-14 |
ビーエーエスエフ ソシエタス・ヨーロピア |
水への溶解性が低い物質の製剤を製造する方法
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
ES2606227T3
(es)
|
2010-02-03 |
2017-03-23 |
Grünenthal GmbH |
Preparación de una composición farmacéutica en polvo mediante una extrusora
|
CA2808541C
(en)
|
2010-09-02 |
2019-01-08 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising an anionic polymer
|
WO2012028319A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising inorganic salt
|
SG191288A1
(en)
|
2010-12-22 |
2013-07-31 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
JP5638151B2
(ja)
|
2010-12-23 |
2014-12-10 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
不正加工抵抗性の(tamperresistant)固形経口剤形
|
KR20140053158A
(ko)
|
2011-07-29 |
2014-05-07 |
그뤼넨탈 게엠베하 |
즉시 약물 방출을 제공하는 탬퍼-저항성 정제
|
AR087360A1
(es)
|
2011-07-29 |
2014-03-19 |
Gruenenthal Gmbh |
Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
|
CA2864949A1
(en)
|
2012-02-28 |
2013-09-06 |
Grunenthal Gmbh |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
JP6282261B2
(ja)
|
2012-04-18 |
2018-02-21 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
不正使用防止および過量放出防止医薬剤形
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
WO2014013311A1
(en)
|
2012-07-16 |
2014-01-23 |
Rhodes Technologies |
Process for improved opioid synthesis
|
EP2872516B1
(en)
|
2012-07-16 |
2017-08-30 |
Rhodes Technologies |
Process for improved opioid synthesis
|
US9149533B2
(en)
|
2013-02-05 |
2015-10-06 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
TW201521769A
(zh)
|
2013-03-15 |
2015-06-16 |
Durect Corp |
具有流變改質劑以減少溶解變異性之組成物
|
CA2913209A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper resistant dosage form with bimodal release profile
|
EP3003279A1
(en)
|
2013-05-29 |
2016-04-13 |
Grünenthal GmbH |
Tamper-resistant dosage form containing one or more particles
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
AU2014295042B2
(en)
|
2013-07-23 |
2017-03-30 |
Mundipharma Pty Limited |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
GB2517000B
(en)
|
2013-08-02 |
2018-05-09 |
Johnson Matthey Plc |
Process for the synthesis of oxymorphone alkaloid and oxymorphone salts
|
MX371372B
(es)
|
2013-11-26 |
2020-01-28 |
Gruenenthal Gmbh |
Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
|
CN106029669B
(zh)
|
2014-01-15 |
2018-04-13 |
罗德科技公司 |
改进的羟二氢吗啡酮合成的方法
|
US9932348B2
(en)
|
2014-01-15 |
2018-04-03 |
Rhodes Technologies |
Process for improved oxycodone synthesis
|
US9062063B1
(en)
|
2014-03-21 |
2015-06-23 |
Johnson Matthey Public Limited Company |
Forms of oxymorphone hydrochloride
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
WO2015181059A1
(en)
|
2014-05-26 |
2015-12-03 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
US9918979B2
(en)
|
2015-01-29 |
2018-03-20 |
Johnson Matthey Public Limited Company |
Process of preparing low ABUK oxymorphone hydrochloride
|
JP2018517676A
(ja)
|
2015-04-24 |
2018-07-05 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時放出および溶媒抽出に対する耐性を有する改変防止製剤
|
WO2017042325A1
(en)
|
2015-09-10 |
2017-03-16 |
Grünenthal GmbH |
Protecting oral overdose with abuse deterrent immediate release formulations
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|